RICERCA ITALIANA     

Programmi di ricerca simili:

• 1 - Epatopatia steatosica non alcolica : studio dei fattori metabolici, genetici e virologici responsabili del danno epatico e della sua evoluzione
• 2 - Interruttori molecolari che controllano l'omeostasi dei sistemi metabolici e vascolari: dai modulatori del RNA a quelli della trasmissione del segnale
• 3 - MECCANISMI CELLULARI E MOLECOLARI COINVOLTI NELL'OMEOSTASI METABOLICA: ASPETTI FISIO-PATOLOGICI
• 4 - Rapporto ospite parassita nelle infezioni da clamidie e spirochete: immunità naturale e metabolismo lipidico studiati con tecniche convenzionali e con DNA microarray
• 5 - Basi Metaboliche e Molecolari dell'Epatopatia associata a Nutrizione Parenterale: ruolo degli steroli vegetali
• 6 - PRODUZIONE E CATABOLISMO DELLA BETA-AMILOIDE IN PAZIENTI CON MALATTIA DI ALZHEIMER E MILD COGNITIVE IMPAIRMENT: STUDI IN VITRO E MARKERS EX VIVO
• 7 - ADIPOSITA' E BILANCIO ENERGETICO:FATTORI ENDOCRINI, MECCANISMI CELLULARI ED ASPETTI FISIO-PATOLOGICI

Classificazione scientifico-disciplinare

• Area scientifico disciplinare: Scienze chimiche
• Area scientifico disciplinare: Scienze biologiche
  • FISIOLOGIA
  • BIOCHIMICA
• Area scientifico disciplinare: Scienze mediche
  • MEDICINA INTERNA
  • GASTROENTEROLOGIA
  • ENDOCRINOLOGIA

Classificazione brevettuale

• CHEMISTRY; METALLURGY
  • BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF (biocides, pest repellants or attractants, or plant growth regulators, containing micro-organisms, viruses, microbial fungi, enzymes, fermentates or substances produced by or extracted from micro-organisms or animal material A01N63/00; food compositions A21, A23; medicinal preparations A61K; chemical aspects of, or use of materials for, bandages, dressings, absorbent pads or surgical articles A61L; fertilisers C05); PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS (preservation of living parts of humans or animals A01N1/02); MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (micro-biological testing media C12Q)

Classificazione geografica

• Regione: Emilia Romagna

Bibliografia

1) Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
2) Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
3) Francis GA, Fayard E, Picard F, Auwerx J. Nuclear receptors and the control of metabolism. Annu Rev Physiol 2003; 65: 261-311.
4) Chiang JYL. Bile acid regulation of hepatic physiology. III. Bile acids and nuclear receptors. Am J Physiol (Gastrointest Liver Physiol) 2003; 284: G349-G356.
5) Javitt NB. Bile acid synthesis from cholesterol: regulatory and auxiliary pathways. FASEB J 1994; 8: 1308-1311.
6) Fu X, Menke EG, Chen Y, Zhou G, MacMaul KL, Wright SD, Sparrow CP, Lund EG. 27-hydroxycholesterol is an endogenous ligand to liver X receptors in cholesterol loaded cells. J Biol Chem 2001; 276: 38378-38387.
7) De Fabiani E, Mitro N, Gilardi F, Caruso D, Galli G, Crestani M. Coordinated control of cholesterol catabolism to bile acid and of gluconeogenesis via a novel mechanism of transcription regulation linked to the fasted-to-fed cycle. J Biol Chem 2003; 278: 39124-39132.
8) Han SI, Studer E, Gupta S, Fang Y, Qiao L, Li W, Grant S, Hylemon PB, Dent P. Bile acids enhance the activity of the insulin receptor and glycogen synthase in primary rodent hepatocytes. Hepatology 2004; 39: 456-463.
9) Kast HR, Nguyen CM, Sinal CJ, Jones SA, Laffitte BA, Reue K, Gonzalez FJ, Willson TM, Edwards PA. Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids. Mol Endocrinol 2001; 15: 1720-1728.
10) Claudel T, Inoue Y, Barbier O, Duran-Sandoval D, Kosykh V, Fruchart J, Fruchart JC, Gonzalez FJ, Staels B. Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. Gastroenterology 2003; 125: 544-555.
11) Davis RA, Hui TY. Atherosclerosis is a liver disease of the heart. Arterioscler Thromb Vasc Biol 2001; 21: 887-898.
12) Pineda Torra I, Claudel T, Duval C, Kosykh V, Fruchart JC, Staels B. Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor. Mol Endocrinol 2003; 17: 259-272.
13) Einarsson K, Hellström K, Kallner M. Bile acid kinetics in relation to sex, serum lipids, body weights, and gallbladder disease in patients with various types of hyperlipoproteinemia. J Clin Invest 1974; 54: 1301-1311.
14) Angelin B, Hershon KS, Brunzell JD. Bile acid metabolism in hereditary forms of hypertriglyceridemia: evidence for an increased synthesis rate in monogenic familial hypertriglyceridemia. Proc Natl Acad Sci USA 1987; 84: 5434-5438.
15) Bertolotti M, Concari M, Loria P, Abate N, Pinetti A, Guicciardi ME, Carulli N. Effects of different phenotypes of hyperlipoproteinemia and of treatment with fibric acid derivatives on the rates of cholesterol 7alpha-hydroxylation in humans. Arterioscler Thromb Vasc Biol 1995; 15: 1064-1069.
16) Carulli N, Ponz del Leon M, Podda M, Zuin M, Strata A, Frigerio G, Digrisolo A. Chenodeoxycholic acid and ursodeoxycholic acid effects in endogenous hypertriglyceridemias. A controlled double-blind trial. J Clin Pharmacol 1981; 21: 436-442.
17) Gylling H, Farkkila M, Vuoristo M, Miettinen TA. Metabolism of cholesterol and low- and high-density lipoproteins in primary biliary cirrhosis: cholesterol absorption and synthesis related to lipoprotein levels and their kinetics. Hepatology 1995; 21: 89-95.
18) Del Puppo M, Galli Kienle M, Petroni ML, Crosignani A, Podda M. Serum 27-hydroxycholesterol in patients with primary biliary cirrhosis suggests alteration of cholesterol catabolism to bile acids via the acidic pathway. J Lipid Res 1998; 39: 2477-2482.
19) Bertolotti M, Carulli L, Concari M, Martella P, Loria P, Tagliafico E, Ferrari S, Del Puppo M, Amati B, De Fabiani E, Crestani M, Amorotti C, Manenti A, Carubbi F, Pinetti A, Carulli N. Suppression of bile acid synthesis, but not of cholesterol 7alpha-hydroxylase expression in vitro, by obstructive cholestasis in human subjects. Hepatology 2001; 34: 234-242.
20) Longo M, Crosignani A, Battezzati PM, Squarcia Giussani C, Invernizzi P, Zuin M, Podda M. Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis. Gut 2002; 51: 265-269.
21) Attili AF, Capocaccia R, Carulli N, Festi D, Roda E, Barbara L, Capocaccia L, Menotti A, Okolicsanyi L, Ricci G, Lalloni L, Mariotti S, Sama C, Scafato E. Factors associated with gallstone disease in the MICOL experience. Multicenter Italian Study on Epidemiology of Cholelithiasis. Hepatology 1997; 26: 809-818.
22) Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998; 352: 1881-1883.
23) Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 1997; 89: 331-340.
24) Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002; 109: 1125-1131.
25) Peet DJ, Turley SD, Ma WM, Janowski BA, Lobaccaro J-MA, Hammer RE, Mangelsdorf DJ. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXRalpha. Cell 1998; 93: 693-704.
26) DeBose-Boyd R, Ou J, Goldstein JL, Brown MS. Expression of sterol regulatory element-binding protein 1c (SREBP-1c) mRNA in rat hepatoma cells requires endogenous LXR ligands. Proc Natl Acad Sci USA 2001; 98: 1477-1482.
27) Levy JR, Clore JN, Stevens W. Dietary n-3 polyunsaturated fatty acids decrease hepatic triglycerides in Fischer 344 rats. Hepatology 2004; 39: 608-616.
28) Tai ES, Demissie S, Cupples LA, Corella D, Wilson PW, Schaefer EJ, Ordovas JM. Association between the PPARA L162V polymorphism and plasma lipid levels: the Framingham Offspring Study. Arterioscer Thromb Vasc Biol 2002; 22: 805-810.
29) Jamshidi Y, Montgomery HE, Hense HW, Myerson SG, Torra IP, Staels B, World MJ, Doering A, Erdmann J, Hengstenberg C, Humphries SE, Schunkert H, Flavell DM. Peroxisome proliferator-activated receptor alpha gene regulates left ventricular growth in respone to exercise and hypertension. Circulation 2002; 105: 950-955.
30) Babaya N, Ikegami H, Fujisawa T, Nojima K, Itoi-Babaya M, Inoue K, Nakura J, Abe M, Yamamoto M, Jin JJ, Wu Z, Miki T, Fukuda M, Ogihara T. Association of I27L polymorphism of hepatocyte nuclear factor-1alpha gene with high-density lipoprotein cholesterol level. J Clin Endocr Metab 2003; 88: 2548-2551.

Parole Chiave

ACIDI BILIARI; SINDROME METABOLICA; RECETTORI NUCLEARI; ATEROSCLEROSI; INSULINO-RESISTENZA; COLESTEROLO 7ALFA-IDROSSILASI; IPERLIPEMIA; SINTESI DI LIPOPROTEINE; STEROLO 27-IDROSSILASI